Alterity Therapeutics (ATHE) Total Current Liabilities (2009 - 2026)

Alterity Therapeutics has reported Total Current Liabilities for 18 years, with the latest figure at $2.2 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 1.1% year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was $2.2 million, a 1.1% decrease from a year earlier, with the FY2026 full-year figure at $2.2 million, up 163.7% from the prior year.
• Total Current Liabilities was $2.2 million for Q2 2026 at Alterity Therapeutics, up from $1.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $4.2 million in Q2 2022, with the low at $43820.2 in Q2 2023.
• Average Total Current Liabilities over 5 years is $2.1 million, with a median of $2.2 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities plunged 98.95% in 2023, then jumped 4112.61% in 2025.
• Over 5 years, Total Current Liabilities stood at $3.4 million in 2022, then dropped by 14.91% to $2.9 million in 2023, then sank by 39.23% to $1.8 million in 2024, then retreated by 4.49% to $1.7 million in 2025, then surged by 31.89% to $2.2 million in 2026.
• The last three Total Current Liabilities figures came in at $2.2 million (Q2 2026), $1.7 million (Q4 2025), and $2.3 million (Q2 2025), per Business Quant data.